These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29514679)

  • 41. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men.
    Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L
    Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modeling cost-effectiveness of cervical cancer screening in Hungary.
    Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
    Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening.
    Davidović M; Zielonke N; Lansdorp-Vogelaar I; Segnan N; de Koning HJ; Heijnsdijk EA
    Value Health; 2021 Mar; 24(3):353-360. PubMed ID: 33641769
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Economic evaluation on breast cancer screening in mainland China: a systematic review].
    Wang L; Shi JF; Huang HY; Zhu J; Li J; Fang Y; Dai M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Dec; 37(12):1662-1669. PubMed ID: 27998418
    [No Abstract]   [Full Text] [Related]  

  • 47. Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin Lymphoma.
    Furzer J; Tessier L; Hodgson D; Cotton C; Nathan PC; Gupta S; Pechlivanoglou P
    J Natl Cancer Inst; 2020 Jan; 112(1):63-70. PubMed ID: 31070751
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-Effectiveness Analysis of Breast Cancer Screening in Rural Iran.
    Zehtab N; Jafari M; Barooni M; Nakhaee N; Goudarzi R; Larry Zadeh MH
    Asian Pac J Cancer Prev; 2016; 17(2):609-14. PubMed ID: 26925651
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decision tree-Markov model of perinatal depression screening: a cost-utility analysis.
    Yang Y; Zheng R; Yang L; Huang X; Zhang T
    Front Public Health; 2024; 12():1308867. PubMed ID: 38832225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening.
    Kuo MJ; Chen HH; Chen CL; Fann JC; Chen SL; Chiu SY; Lin YM; Liao CS; Chang HC; Lin YS; Yen AM
    World J Gastroenterol; 2016 Mar; 22(12):3460-70. PubMed ID: 27022228
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
    Lin OS; Keeffe EB; Sanders GD; Owens DK
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1159-72. PubMed ID: 15153169
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
    Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is mammography for breast cancer screening cost-effective in both Western and asian countries?: results of a systematic review.
    Yoo KB; Kwon JA; Cho E; Kang MH; Nam JM; Choi KS; Kim EK; Choi YJ; Park EC
    Asian Pac J Cancer Prev; 2013; 14(7):4141-9. PubMed ID: 23991967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of testing for breast cancer susceptibility genes.
    Holland ML; Huston A; Noyes K
    Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
    Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
    Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis for breast cancer screening: double reading versus single + CAD reading.
    Sato M; Kawai M; Nishino Y; Shibuya D; Ohuchi N; Ishibashi T
    Breast Cancer; 2014 Sep; 21(5):532-41. PubMed ID: 23104393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer.
    Hayman JA; Hillner BE; Harris JR; Weeks JC
    J Clin Oncol; 1998 Mar; 16(3):1022-9. PubMed ID: 9508186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Personalized Mammography Screening and Screening Adherence-A Simulation and Economic Evaluation.
    Arnold M; Quante AS
    Value Health; 2018 Jul; 21(7):799-808. PubMed ID: 30005752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.